Association of Tumor Size with Risk of Lymph Node Metastasis in Clear Cell Renal Cell Carcinoma: A Population-Based Study.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
07
2020
revised:
14
10
2020
accepted:
18
10
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
The purpose of this article was to explore the association of tumor size with lymph node metastases (LNM) risk in patients with clear cell renal cell carcinoma (ccRCC). Based on the Surveillance, Epidemiology, and End Result (SEER) database, patients diagnosed with ccRCC from 1988 to 2015 were included in this study. For each patient, personal characteristics, clinicopathological data, and survival outcomes were, respectively, collected. Subsequently, the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to investigate the potential risk factors for LNM in ccRCC. Finally, Kaplan-Meier (KM) survival plots of overall survival (OS) and ccRCC-specific survival (CSS) were evaluated on the basis of different tumor sizes. A total of 8,292 patients were finally enrolled in the study, 1,170 of whom (14.11%) had LNM. According to the heatmap, we could intuitively interpret that larger tumor size was related to an increased risk of LNM obviously. The risk of LNM was evidently greater for larger tumor size (4-7 cm: OR = 2.415, 95% CI = 1.708-3.415; 7-10 cm: OR = 3.746, 95% CI = 2.677-5.242; and >10 cm: OR = 4.617, 95% CI = 3.302-6.457) compared with smaller tumor size (≤4 cm). According to the KM survival plots of OS and CSS, we observed a gradual decline in survival with increasing tumor size, while the smallest tumor size had the best survival outcomes. These results indicated the positive relationship of tumor size with risk of LNM in ccRCC. And we also noticed continual decrease survival rates of OS and CSS with increasing tumor size.
Identifiants
pubmed: 33178275
doi: 10.1155/2020/8887782
pmc: PMC7648693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8887782Informations de copyright
Copyright © 2020 Yunlai Zhi et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Cancer. 2009 Apr 1;115(7):1465-71
pubmed: 19195042
Cancer. 2008 Jul 1;113(1):84-96
pubmed: 18470927
BJU Int. 2012 May;109(10):1463-7
pubmed: 21933329
Radiographics. 2017 Nov-Dec;37(7):2026-2042
pubmed: 29131770
Urologe A. 1992 Mar;31(2):70-5
pubmed: 1561729
J Urol. 2015 Jun;193(6):1911-6
pubmed: 25524244
Lancet. 2007 Dec 22;370(9605):2071-3
pubmed: 18156012
Eur Urol. 2015 Sep;68(3):506-15
pubmed: 25524810
Eur Urol. 2019 Jan;75(1):74-84
pubmed: 30243799
J Urol. 2003 Jun;169(6):2076-83
pubmed: 12771723
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Urology. 2010 Feb;75(2):266-70
pubmed: 19913892
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
BJU Int. 2008 Nov;102(10):1385-8
pubmed: 18710458
Urol Oncol. 2020 May;38(5):537-544
pubmed: 32122729
J Urol. 2009 Jul;182(1):41-5
pubmed: 19450840
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Springerplus. 2016 Jun 27;5(1):899
pubmed: 27386346
Int J Urol. 2013 Apr;20(4):372-80
pubmed: 23039208
J Urol. 2017 Aug;198(2):289-296
pubmed: 28274620
Radiographics. 2018 Nov-Dec;38(7):2021-2033
pubmed: 30339517
J Urol. 2001 Jul;166(1):68-72
pubmed: 11435825
J Urol. 2003 Dec;170(6 Pt 1):2217-20
pubmed: 14634382
Onco Targets Ther. 2018 Sep 17;11:5873-5878
pubmed: 30271170
Urology. 2003 Dec;62(6):1024-8
pubmed: 14665348